Patents Assigned to Galderma Research & Development S.N.C.
  • Patent number: 7838558
    Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: November 23, 2010
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Michael Graeber, Janusz Czernielewski
  • Publication number: 20070275978
    Abstract: The invention relates to the use of an antagonist of at least one receptor chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor, for the preparation of a pharmaceutical composition for treating rosacea.
    Type: Application
    Filed: February 17, 2005
    Publication date: November 29, 2007
    Applicant: Galderma Research & Development S.N.C.
    Inventors: Fabrizio Dolfi, Irina Safonova
  • Publication number: 20070189985
    Abstract: The invention relates to the use of a compound which modifies, and advantageously inhibits, the secretion of at least one interleukin chosen from the group comprising IL-5, IL-6 and IL-10, for the preparation of a pharmaceutical composition for treating rosacea.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 16, 2007
    Applicant: Galderma Research & Development S.N.C.
    Inventors: Fabrizio Dolfi, Irina Safonova
  • Publication number: 20070065471
    Abstract: Cosmetic/pharmaceutical compositions useful for regulating the size of sebaceous glands and, in particular, for inhibiting sebum production, or for treating pathologies entailing an overproduction of sebum, or for treating greasy skin and/or a scalp prone to dandruff, contain thus effective amounts of at least one activator of PPAR type receptors.
    Type: Application
    Filed: June 1, 2006
    Publication date: March 22, 2007
    Applicant: GALDERMA RESEARCH & DEVELOPMENT S.N.C.
    Inventors: Andre Jomard, Michel Rivier
  • Publication number: 20070043046
    Abstract: Novel pharmaceutical/cosmetic compositions contain at least one biaromatic ligand activator of a PPAR? receptor, such biaromatic ligand having the structural formula (I): and are well suited, inter alia, for regulating and/or restoring skin lipid metabolism, for treating a wide variety of dermatological afflictions, and for preventing and/or treating the signs of aging and/or dry skin.
    Type: Application
    Filed: August 18, 2006
    Publication date: February 22, 2007
    Applicant: GALDERMA RESEARCH & DEVELOPMENT S.N.C.
    Inventors: Jean-Michel Bernardon, Laurence Clary, Eric Terranova
  • Patent number: 6908939
    Abstract: Novel pharmaceutical/cosmetic compositions contain at least one biaromatic ligand activator of a PPAR? receptor, such biaromatic ligand having the structural formula (I): and are well suited, inter alia, for regulating and/or restoring skin lipid metabolism, for treating a wide variety of dermatological afflictions, and for preventing and/or treating the signs of aging and/or dry skin.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: June 21, 2005
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Jean-Michel Bernardon, Laurence Clary, Eric Terranova
  • Patent number: 6858647
    Abstract: A variety of retinoid compounds well suited for preventively or curatively treating a bacterial colonization infesting/infecting an individual subject exhibit pronounced antibacterial activity, notably pronounced antibacterial activity in respect of the bacterium Staphylococcus aureus, and are also well suited for the cleansing/deodorizing of human skin.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: February 22, 2005
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Johannes Voegel, Marie-Thérèse Cavey
  • Patent number: 6825360
    Abstract: The invention relates to novel bicyclic aromatic compounds which have the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: November 30, 2004
    Assignee: Galderma Research & Development S.N.C.
    Inventor: Jean-Michel Bernardon
  • Publication number: 20040039038
    Abstract: The invention relates to novel biaromatic compounds which correspond to the general formula (I) below: 1
    Type: Application
    Filed: February 10, 2003
    Publication date: February 26, 2004
    Applicant: GALDERMA RESEARCH & DEVELOPMENT S.N.C.
    Inventors: Jean-Michel Bernardon, Laurence Clary
  • Patent number: 6689922
    Abstract: The invention concerns novel bi-aromatic compounds having the formula: which are analogs of vitamin D, the process of preparing them, as well as their use in pharmaceutical compositions in human or veterinary medicine, particularly in dermatology, cancer treatment, treatment of auto-immune diseases, and in organ or tissue transplants. Cosmetic compositions and methods of use are also included.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: February 10, 2004
    Assignee: Galderma Research & Development S.N.C.
    Inventor: Jean-Michel Bernardon
  • Patent number: 6686386
    Abstract: The present invention relates to pharmaceutical and cosmetic compositions comprising at least one agonist ligand, which is specific for receptors of the RAR-&ggr; type, which are characterized as inducers of apoptosis in at least one cell population in which apoptosis can be induced by activating receptors of the RAR-&ggr; type. In one aspect of the present invention, there is provided a method of combating photoinduced or chronological ageing of skin, said method comprising administering an effective amount of at least one agonist ligand which is specific for receptors of the RAR-&ggr; type to combat photoinduced or chronological aging of skin, wherein the agonist ligand has a ratio R which is equal to or greater than 10.
    Type: Grant
    Filed: November 2, 1999
    Date of Patent: February 3, 2004
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Laszlo Fesus, Zsuzsa Szondy, Uwe Reichert
  • Patent number: 6632963
    Abstract: Novel pharmaceutically/cosmetically-active bicyclic aromatic compounds have the structural formula (I): in which Ar1 is a radical having one of the structural formulae (a)-(c): Ar2 is a radical having one of the following formulae (d)-(h): and X is a radical having one of the following formulae (i)-(l): and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: October 14, 2003
    Assignee: Galderma Research & Development S.N.C.
    Inventor: Jean-Michel Bernardon
  • Patent number: 6462064
    Abstract: The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: October 8, 2002
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
  • Patent number: 6444709
    Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: September 3, 2002
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Philippe Diaz, Jean-Michel Bernardon
  • Patent number: 6214878
    Abstract: The invention relates to novel stilbene compounds having the general formula (I): as well as to pharmaceutical compositions for use in human or veterinary medicine, including dermatological, rheumatic, respiratory, cardiovascular and ophthalmic conditions and cosmetic compositions and methods of use thereof.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: April 10, 2001
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Jean-Michel Bernardon, Bruno Charpentier